Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a sharehold ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

A potential world-first cure for hepatitis B, a breakthrough treatment for a rare, life-threatening childhood disease, and a ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Lady T is joined by Dr. Mona Gohara, Medical Dermatologist and Associate Clinical Professor at the Department of Dermatology ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

After starting therapy for psoriasis, Asempa usually has a follow-up visit at 3 to 4 months. Patient feedback at that point carries a lot of weight with respect to next steps.